AstraZeneca Beats Expectations, China Momentum Continues -- Earnings Review

Date : 10/24/2019 @ 1:09PM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7659.0  2.0 (0.03%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca Beats Expectations, China Momentum Continues -- Earnings Review

Astrazeneca (LSE:AZN)
Historical Stock Chart

6 Months : From Jul 2019 to Jan 2020

Click Here for more Astrazeneca Charts.

By Carlo Martuscelli

 

AstraZeneca PLC (AZN.LN) reported results for the third quarter on Thursday. Here's what we looked at:

 

SALES: The British drug maker said sales in the quarter totaled $6.41 billion, ahead of analyst forecasts of $6.13 billion.

 

CORE EPS: Core earnings per share, a company metric looked at by analysts, was 99 cents, slightly exceeding market consensus expectations of 97 cents.

 

WHAT WE WATCHED:

 

TAGRISSO: Cancer drug Tagrisso confirmed its place as a key revenue driver for the company, accounting for 13% of its total sales. The drug generated $891 million in the quarter--which Shore Capital says is a 4% beat to analyst consensus expectations. The performance of the oncology portfolio overall was strong, with sales increasing by 48% at constant exchange rates.

 

CHINA: The FTSE 100-listed company's performance in China didn't seem to be losing steam despite earlier warnings by Chief Executive Pascal Soriot. Astra said that sales in the region increased by 40% excluding currency effects. Shore Capital said that it expects investors will react well to the drug maker's strength in emerging markets.

 

CASH FLOW: Earlier in the year, analysts had highlighted cash flow as one issue facing the company, particularly after a large deal to acquire part of the rights to the cancer asset DS-8201, but these seem to have abated. "Cash is the lifeblood of any company, so it is particularly encouraging to see such a strong performance here with the best part of a $1 billion inflow in the period after capital expenditure," says AJ Bell.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

(END) Dow Jones Newswires

October 24, 2019 08:54 ET (12:54 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200126 15:34:38